After finishing at $20.25 in the prior trading day, Kura Oncology Inc (NASDAQ: KURA) closed at $20.74, up 2.42%. In other words, the price has increased by $+0.49 from its previous closing price. On the day, 543046 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of KURA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.71 and its Current Ratio is at 16.71. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on December 22, 2023, initiated with a Buy rating and assigned the stock a target price of $26.
On August 11, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $31.
On July 27, 2023, Scotiabank started tracking the stock assigning a Sector Perform rating and target price of $10.50.Scotiabank initiated its Sector Perform rating on July 27, 2023, with a $10.50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 30 when DALE STEPHEN sold 4,825 shares for $21.55 per share. The transaction valued at 103,980 led to the insider holds 38,817 shares of the business.
DALE STEPHEN sold 7,158 shares of KURA for $127,416 on Jan 29. The Chief Medical Officer now owns 43,642 shares after completing the transaction at $17.80 per share. On Jan 29, another insider, DOYLE THOMAS JAMES, who serves as the SVP, Finance & Accounting of the company, sold 2,318 shares for $17.80 each. As a result, the insider received 41,262 and left with 48,093 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KURA now has a Market Capitalization of 1.54B and an Enterprise Value of 1.11B.
Stock Price History:
The Beta on a monthly basis for KURA is 0.85, which has changed by 69.88% over the last 52 weeks, in comparison to a change of 28.18% over the same period for the S&P500. Over the past 52 weeks, KURA has reached a high of $22.92, while it has fallen to a 52-week low of $7.41. The 50-Day Moving Average of the stock is 16.66, while the 200-Day Moving Average is calculated to be 11.89.
Shares Statistics:
The stock has traded on average 1.51M shares per day over the past 3-months and 848.91k shares per day over the last 10 days, according to various share statistics. A total of 68.31M shares are outstanding, with a floating share count of 64.63M. Insiders hold about 15.11% of the company’s shares, while institutions hold 90.39% stake in the company. Shares short for KURA as of Jan 31, 2024 were 9.37M with a Short Ratio of 6.19, compared to 9.26M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 12.38% and a Short% of Float of 12.56%.
Earnings Estimates
Its stock is currently analyzed by 14 different market analysts. On average, analysts expect EPS of -$0.55 for the current quarter, with a high estimate of -$0.49 and a low estimate of -$0.68, while EPS last year was -$0.49. The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.47 and low estimates of -$0.72.
Analysts are recommending an EPS of between -$1.97 and -$2.21 for the fiscal current year, implying an average EPS of -$2.08. EPS for the following year is -$2.22, with 14 analysts recommending between -$1.84 and -$3.08.
